Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients
- Quan Yuan1,
- Liu-Wei Song1,
- Chun-Jen Liu2,
- Zhuo Li3,
- Ping-Guo Liu4,
- Cheng-Hao Huang1,
- Yan Yan3,
- Sheng-Xiang Ge1,
- Ying-Bin Wang1,
- Cheng-Yuan Peng5,
- Jun Zhang1,
- Jia-Horng Kao2,
- Ding-Shinn Chen2,
- Pei-Jer Chen2,
- Ning-Shao Xia1
- 1National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China
- 2Graduate Institute of Clinical Medicine and Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
- 3Youan Hospital, Capital Medical University, Beijing, China
- 4Zhongshan Hospital and College of Medicine, Xiamen University, Xiamen, China
- 5China Medical University Hospital, China Medical University, Taichung, Taiwan
- Correspondence to Professor Jun Zhang, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Science, Xiamen University, Siming South Road No. 422, Xiamen 361005. China; zhangj{at}xmu.edu.cn
-
Contributors JZ, NSX and PJC are co-corresponders for this paper. Study concept and design: QY, JZ, P-JC and N-SX. Acquisition of data: QY, L-WS, C-JL, C-HH, S-XG and Y-BW. Analysis and interpretation of data: QY, L-WS, P-JC. Drafting of the manuscript: QY and P-JC. Critical revision of the manuscript for important intellectual content: P-JC, JZ, J-HK, D-SC and N-SX. Statistical analysis: QY and L-WS. Technical, or material support: C-JC, ZL, P-GL, YY and C-YP. Obtained funding: S-XG, JZ and N-SX. Study supervision: JZ and N-SX. Approval of the final version of the manuscript: P-JC, JZ and N-SX.
- Accepted 15 May 2012
- Published Online First 14 June 2012
- Hepatitis B virus
- quantitative anti-HBc
- treatment response prediction
- hepetitis
- hepatitis B
- hepatitis E
- infectious disease
- hepatitis C
- hepatocellular carcinoma
- hepatoma
- hepatitis D
- liver disease in pregnancy
- genetics
- liver
We read with interest the recent article by Dandri emphasising the use of novel quantitative biomarkers as tools for predicting treatment response and disease progression in chronic hepatitis B infection (CHB).1 The authors carried out a comprehensive review of the clinical implications of quantitative measurement of viral biomarkers both in blood and in liver, such as: serum HBsAg, serum HBeAg and intrahepatic cccDNA, based on current knowledge.1 In addition to these, …








